Results 261 to 270 of about 383,968 (297)

Incidence of skeletal-related events (SREs) among prostate cancer patients.

Journal of Clinical Oncology, 2013
e16035 Background: Skeletal related events (SREs) occur in men with prostate cancer and may result from both bone metastases and exposure to androgen deprivation therapy (ADT). The objective of this study was to quantify the incidence of SREs in patients with prostate cancer treated with ADT or orchiectomy in clinical practice.
Marianne Ulcickas Yood, Teresa Maria Zyczynski, Karen Wells, Deborah Casso, Benjamin Gutierrez, Kimberley J. Woodcroft, Shinta Cheng   +6 more
openaire   +1 more source

Skeletal-related events and mortality among older men with advanced prostate cancer

Journal of Geriatric Oncology, 2014
Skeletal-related events (SREs) are defined as a cluster of events including clinical diagnoses and treatment. Using claims data, the burden of SREs as a group has been reported among patients with cancer. We investigate the mortality impact of subcomponents of SREs, a topic that has received limited attention among older men.We analyzed prostate cancer
Eberechukwu, Onukwugha, Candice, Yong, C Daniel, Mullins, Brian, Seal, Diane, McNally, Arif, Hussain   +5 more
openaire   +2 more sources

Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer

Bone, 2016
Cancer cells can alter physiological mechanisms within bone resulting in high bone turnover, and consequently in skeletal-related events (SREs), causing severe morbidity in affected patients. The goals of bone targeted therapy, as bisphosphonates and denosumab, are the reduction of incidence and the delay in occurrence of the SREs, to improve quality ...
IRELLI, AZZURRA, COCCIOLONE, VALENTINA, Cannita, Katia, Zugaro, Luigi, DI STASO, MARIO, Lanfiuti Baldi, Paola, PARADISI, STEFANIA, Sidoni, Tina, RICEVUTO, Enrico, FICORELLA, Corrado   +9 more
openaire   +2 more sources

Skeletal-related events and prognosis in urothelial cancer patients with bone metastasis

International Journal of Clinical Oncology, 2017
The aim of the present study was to elucidate the details of bone metastasis (BM) and the resulting skeletal-related events (SREs), and survival and prognostic factors, in urothelial cancer (UC) patients with BM.A total of 48 UC patients with BM who were treated at our institution between 1994 and 2013 were enrolled.
Yusuke Tsuda, Tohru Nakagawa, Yusuke Shinoda, Atsushi Kanatani, Taketo Kawai, Satoru Taguchi, Yukio Yamada, Ryoko Sawada, Haruki Kume, Yukio Homma, Sakae Tanaka, Hirotaka Kawano   +11 more
openaire   +2 more sources

Update on the Pharmacological Prevention of Skeletal-related Events in Cancer Patients

Orthopedics, 2011
Metastases to the bone are a frequent complication of advanced cancer. Bone metastases have been linked to skeletal-related events, which is the composite endpoint used in clinical trials evaluating therapy to minimize these complications. This article discusses bisphosphonates, which are the historical standard for the prevention of skeletal-related ...
Kenneth, Kennedy, Hetalkumari, Patel
openaire   +2 more sources

Bone Health: Prevention of Skeletal-Related Events and Palliative Care

2012
Bone health in patients with prostate cancer has been an ever-growing field for almost a decade now. Beyond the realization that patients with prostate cancer suffer from osteopenia at the outset and need some sort of regimen to maintain their bone density, it is becoming increasingly clear that bone decay related to hormonal therapies can result in ...
Jean-Baptiste Lattouf, Fred Saad
openaire   +1 more source

Analysis of skeletal-related events in breast cancer and response to therapy

Seminars in Oncology, 2001
The skeleton is a common site for the spread of metastatic cancer and skeletal complications are a cause of significant morbidity and mortality. Treatment of skeletal morbidity is therefore an essential component of therapy for cancer patients with bone metastases. Bisphosphonates are currently the treatment of choice for skeletal complications.
openaire   +2 more sources

Minimally Invasive Treatment of Skeletal-Related Events

2023
Amata Thongphetsavong Gautam, Frank Hertel   +1 more
openaire   +1 more source

Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.

Oncology (Williston Park, N.Y.), 2015
Skeletal-related events contribute substantially to morbidity, mortality and cost in men with metastatic castration-resistant prostate cancer (mCRPC). There are five agents available for treatment in mCRPC that reduce skeletal-related events. Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium ...
Julie N, Graff, Tomasz M, Beer
openaire   +1 more source

Decreased incidence of skeletal-related events in mRCC

Nature Reviews Urology, 2014
Takeshi Yuasa, Shinji Urakami
openaire   +1 more source